TBPHTheravance Biopharma, Inc.vs its industry peers
A metric-by-metric comparison of Theravance Biopharma, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TBPHEsta | $885M#8 | 16.4x#2 | 3.1x#7 | 8.2x#4 | 66.9%#1 | 287.7%#1 | -3.4%#3 | 36.6%#1 | — | — | 18.5%#1 | — |
| MLTX | $1.0B#1 | — | 2.4x#6 | — | — | -91.1%#12 | — | -53.1%#12 | -491.6%#7 | — | — | — |
| AMPH | $1.0B#2 | 14.0x#1 | 2.3x#5 | 1.4x#2 | -1.7%#6 | -38.5%#8 | 19.5%#1 | 22.0%#2 | 13.2%#1 | 5#1 | -13.1%#2 | — |
| JANX | $1.0B#3 | — | 1.1x#1 | 100.6x#8 | -5.6%#7 | -64.7%#11 | -1576.7%#8 | -12.2%#5 | — | — | — | — |
| KURA | $1.0B#4 | — | 20.8x#13 | 14.9x#5 | 25.2%#3 | -60.2%#10 | -449.9%#6 | -575.4%#13 | — | — | — | — |
| PCRX | $960M#5 | 68.8x#3 | 1.4x#2 | 1.3x#1 | 3.6%#5 | 107.0%#2 | 2.6%#2 | 1.0%#3 | 1.0%#2 | — | — | — |
| FTH | $917M#6 | — | 5.3x#11 | — | — | 30.1%#5 | — | -12.2%#4 | -15.2%#3 | — | — | — |
| LXRX | $897M#7 | — | 5.1x#10 | 18.0x#6 | 60.2%#2 | 74.9%#3 | -98.2%#5 | -28.8%#7 | -26.4%#5 | — | — | — |
| WVE | $879M#9 | — | 1.9x#3 | 20.6x#7 | -60.5%#9 | -110.7%#13 | -504.1%#7 | -45.1%#11 | — | — | — | — |
| IMMX | $869M#10 | — | 3.8x#8 | — | — | -36.0%#7 | — | -12.8%#6 | — | — | — | — |
| OLMA | $857M#11 | — | 2.0x#4 | — | — | -25.5%#6 | — | -37.7%#8 | — | — | — | — |
| ARDX | $846M#12 | — | 5.7x#12 | 2.1x#3 | 22.1%#4 | -59.0%#9 | -10.1%#4 | -41.6%#10 | -52.3%#6 | — | -48.0%#3 | — |
| GERN | $838M#13 | — | 3.8x#9 | 3537.7x#9 | -60.2%#8 | 52.2%#4 | -28938.8%#9 | -38.2%#9 | -24.8%#4 | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice